Fundraising FoxHarvard Apparatus Regenerative Technology
OTC: HRGNHolliston, US · Founded 2012 · Delaware corporation
Find your way into Harvard Apparatus Regenerative Technology
Sign up to see every warm intro you have to Harvard Apparatus Regenerative Technology
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Harvard Apparatus Regenerative Technology team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
HRGN (Harvard Apparatus Regenerative Technology, operating Biostage) is a clinical-stage regenerative medicine company developing treatments for esophageal conditions, including a therapy for esophageal atresia, a congenital defect affecting newborns. Its lead candidate entered a Phase 1 clinical trial in 10 patients at sites including Mayo Clinic and the University of Michigan.
Founders & leadership
WF
William FodorExecutive
JD
Joseph DamasioExecutiveJoseph Damasio is Chief Financial Officer of Harvard Apparatus Regenerative Technology, a publicly traded biotech company developing regenerative medicine treatments for esophageal conditions. He has experience in SEC reporting, financial consolidation, and US GAAP compliance.
DG
David GreenExecutive
SH
Shunfu HuExecutive
TM
Thomas McNaughtonChief Financial Officer
LF
La Francesca SaverioEVP and Chief Medical Officer
JM
James McGorryPresident and CEO
J(
Junli (Jerry) HeChairman and Chief Executive Officer
Board
TL
Ting LiBoard director
JC
Jing ChenBoard director
RP
Ronald PackardBoard director
Reported raises · per SEC filings
Form D private placements$39.4M disclosed across 15 rounds · 2016–2026
▶$2.8MraisedSep 2026 · 6 investors · BiotechnologyRule 506(b)
▶$2.8MraisedSep 2026 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Junli HeExecutive Officer, Director
- Hong YuExecutive Officer
- William FodorExecutive Officer
- Shunfu HuExecutive Officer
- Joseph DamasioExecutive Officer
- Jing ChenDirector
- Ting LiDirector
- James ShmerlingDirector
- Herman SanchezDirector
- David GreenDirector
- Ronald PackardDirector
- Mao ZhangDirector
- Offering amount
- $3M
- Amount sold
- $2.8M
- First sale
- Sep 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$700KraisedJan 2026 · 2 investors · BiotechnologyRule 506(b)
▶$700KraisedJan 2026 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William FodorExecutive Officer
- Ting LiDirector
- Junli HeExecutive Officer, Director
- David GreenDirector
- Hong YuExecutive Officer
- Mao ZhangDirector
- Jing ChenDirector
- Joseph DamasioExecutive Officer
- Ronald PackardDirector
- Herman SanchezDirector
- James ShmerlingDirector
- Shunfu HuExecutive Officer
- Offering amount
- $2M
- Amount sold
- $700K
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedJul 2025 · 2 investors · BiotechnologyRule 506(b)
▶$2MraisedJul 2025 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hong YuExecutive Officer
- James ShmerlingDirector
- Jing ChenDirector
- Joseph DamasioExecutive Officer
- Mao ZhangDirector
- William FodorExecutive Officer
- Ting LiDirector
- Herman SanchezDirector
- David GreenDirector
- Ronald PackardDirector
- Shunfu HuExecutive Officer
- Junli HeExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedAug 2024 · 4 investors · BiotechnologyRule 506(b)
▶$1.5MraisedAug 2024 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William FodorExecutive Officer
- Ting LiDirector
- Jing ChenDirector
- Joseph DamasioExecutive Officer
- David GreenDirector
- Hong YuExecutive Officer
- Ronald PackardDirector
- Junli HeExecutive Officer, Director
- Herman SanchezDirector
- James ShmerlingDirector
- Shunfu HuExecutive Officer
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Apr 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedApr 2023 · 14 investors · BiotechnologyRule 506(b)
▶$6MraisedApr 2023 · 14 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Hong YuExecutive Officer
- Ronald PackardDirector
- Ting LiDirector
- Jing ChenDirector
- Herman SanchezDirector
- David GreenDirector
- Junli HeExecutive Officer, Director
- Joseph DamasioExecutive Officer
- Shunfu HuExecutive Officer
- James ShmerlingDirector
- William FodorExecutive Officer
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.1MraisedJun 2022 · 25 investors · BiotechnologyRule 506(b)
▶$5.1MraisedJun 2022 · 25 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James ShmerlingDirector
- Jing ChenDirector
- David GreenExecutive Officer, Director
- Junli HeDirector
- William FodorExecutive Officer
- Ting LiDirector
- Herman SanchezDirector
- Hong YuExecutive Officer
- Shunfu HuExecutive Officer
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- Sales commissions
- $258.7K
- Placement agents
- Junli He, Hong Yu, David Green, Hu Shu
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.6MraisedSep 2021 · 2 investors · BiotechnologyRule 506(b)
▶$2.6MraisedSep 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- James ShmerlingDirector
- Ting LiDirector
- Jing ChenDirector
- William FodorExecutive Officer
- Shunfu HuExecutive Officer
- Junli HeDirector
- Hong YuExecutive Officer
- Herman SanchezDirector
- Offering amount
- $3M
- Amount sold
- $2.6M
- First sale
- Jun 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$500KraisedAug 2020 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedAug 2020 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Shunfu HuExecutive Officer
- Jeffrey YoungDirector
- James ShmerlingDirector
- William FodorExecutive Officer
- Wei ZhangDirector
- Hong YuExecutive Officer
- Jing ChenDirector
- Ting LiDirector
- Offering amount
- $6.9M
- Amount sold
- $500K
- First sale
- Aug 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Valuation · disclosed
Disclosed events$6.8Mvaluation at IPOFeb 2017 · $0.40/share · 424B4
filing ↗Source: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
In the news
Frequently asked questions
- What does Harvard Apparatus Regenerative Technology do?
- HRGN (Harvard Apparatus Regenerative Technology, operating Biostage) is a clinical-stage regenerative medicine company developing treatments for esophageal conditions, including a therapy for esophageal atresia, a congenital defect affecting newborns. Its lead candidate entered a Phase 1 clinical trial in 10 patients at sites including Mayo Clinic and the University of Michigan.
- How much funding has Harvard Apparatus Regenerative Technology raised?
- Harvard Apparatus Regenerative Technology has disclosed $39.4M raised across 15 rounds.
- Where is Harvard Apparatus Regenerative Technology headquartered?
- Harvard Apparatus Regenerative Technology is headquartered in Holliston, US.